Literature DB >> 11532552

CT stereotaxy guided lateral trans-cerebellar programmable fourth ventriculo-peritoneal shunting for symptomatic trapped fourth ventricle.

R R Sharma1, S J Pawar, R V Devadas, E J Dev.   

Abstract

A trapped fourth ventricle is a rare clinico-radiological entity producing symptoms suggestive of a progressive posterior fossa mass lesion. It is mainly reported in children as a late complication of lateral ventricular shunting to relieve infantile post-meningitic or post-hemorrhagic hydrocephalus. Optional treatment of the trapped fourth ventricle remains controversial. Placement of fourth ventricular shunting via a conventional midline approach can be fraught with complications in about 40% of the patients. Authors report a successful CT Stereotaxy guided high pressure (80 mm H(2)O) programmable fourth ventriculo-peritoneal shunting via a lateral trans-cerebellar approach in a 14-year-old girl with a trapped fourth ventricle, which occurred as a late complication of ventriculo-peritoneal shunting in her infancy. Her preoperative symptoms of raised intracranial pressure, bobble-head doll syndrome and bilateral abducens palsies completely improved following the surgery. Lateral trans-cerebellar stereotactic placement of the fourth ventricular catheter and the use of high-pressure (low flow) programmable shunt (to avoid complications associated with over drainage) are beneficial in some patients with trapped fourth ventricle.

Entities:  

Mesh:

Year:  2001        PMID: 11532552     DOI: 10.1016/s0303-8467(01)00129-9

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

Review 1.  Management strategies for treatment of the trapped fourth ventricle.

Authors:  David H Harter
Journal:  Childs Nerv Syst       Date:  2004-07-15       Impact factor: 1.475

2.  Endoscopic aqueductoplasty: stent or not to stent?

Authors:  Michael J Fritsch; Sven Kienke; H Maximilian Mehdorn
Journal:  Childs Nerv Syst       Date:  2003-12-19       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.